Epiminder Limited (ASX:EPI) has disclosed that the effective date for the change of its registered office address and principal place of business will be 1 April 2027, with the company set to relocate to Suite 1904, Level 19, 7 Spencer Street, Melbourne VIC 3000.

Key Points

  • The effective date of the registered office change is 1 April 2027.
  • The new address will be Suite 1904, Level 19, 7 Spencer Street, Melbourne VIC 3000.
  • The registered office will be open from 9am to 5pm on business days from that date.
  • The update follows the company's earlier disclosure made on 2 November 2026.

Registered Office Relocation Effective Date Confirmed

Epiminder Limited disclosed on 13 November 2026 that the effective date for its change of registered office and principal place of business is 1 April 2027. The filing states that this update is further to the company's announcement made on 2 November 2026. Both the registered office and the principal place of business will transfer to the new location on that date. The disclosure was approved by the Company Secretary.

New Address Details at 7 Spencer Street Melbourne

From 1 April 2027, Epiminder's registered office and principal place of business will be located at Suite 1904, Level 19, 7 Spencer Street, Melbourne VIC 3000. According to the filing, the registered office at this address will be open from 9am to 5pm on business days. The company is a medical device and information solutions company focused on developing diagnostic and treatment tools for epilepsy and other seizure disorders where continuous monitoring is required, and is headquartered in Melbourne, Australia, with offices in the United States.

Company Background and Minder® Device

Epiminder was founded in 2017 by Professor Mark Cook together with the Bionics Institute, St Vincent's Hospital, the University of Melbourne, and Cochlear Limited. The company's Minder® device is described in the filing as a minimally invasive implantable continuous EEG Monitoring device that provides clinicians and patients with long-term, objective data on brain electrical activity. The Minder® System was authorised by the FDA via the de novo pathway and is being used in the DETECT post-market study as a marketed device.